|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA] |
CTD |
PMID:20083572 PMID:23227865 PMID:23362264 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein] |
CTD |
PMID:16452108 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases expression affects localization increases activity |
EXP ISO |
Bucladesine inhibits the reaction [estradiol-17 beta-glucuronide affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein] Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine results in increased activity of and affects the localization of ABCC2 protein; Dactinomycin inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; verlukast inhibits the reaction [Bucladesine results in increased activity of ABCC2 protein] Bucladesine results in increased expression of ABCC2 mRNA; Bucladesine results in increased expression of ABCC2 protein |
CTD |
PMID:12029626 PMID:26049102 PMID:29052767 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Ache |
acetylcholinesterase |
increases activity increases expression |
EXP |
Bucladesine results in increased activity of ACHE protein; Bucladesine results in increased activity of ACHE protein alternative form Bucladesine results in increased expression of ACHE mRNA |
CTD |
PMID:18514641 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adm |
adrenomedullin |
decreases expression |
ISO |
Bucladesine results in decreased expression of ADM mRNA |
CTD |
PMID:19253104 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein]; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]; Losartan inhibits the reaction [AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]] |
CTD |
PMID:36682589 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects localization multiple interactions increases activity |
ISO |
Bucladesine affects the localization of AHR protein Bucladesine affects the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] Bucladesine results in increased activity of AHR protein |
CTD |
PMID:15972329 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ahrr |
aryl-hydrocarbon receptor repressor |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AHRR mRNA] |
CTD |
PMID:21979172 |
|
NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:28,993,634...29,088,673
|
|
G |
Ak5 |
adenylate kinase 5 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of AK5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA |
CTD |
PMID:22859313 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Antxr1 |
ANTXR cell adhesion molecule 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ANTXR1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:119,590,770...119,778,232
Ensembl chr 4:119,590,771...119,778,232
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ANXA2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; Probucol inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; T0901317 promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol] |
CTD |
PMID:20083572 PMID:23227865 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Ar |
androgen receptor |
multiple interactions |
EXP |
[Quercetin co-treated with Bucladesine] results in increased expression of AR mRNA |
CTD |
PMID:23200735 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ARHGEF2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355
|
|
G |
Atf1 |
activating transcription factor 1 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]] |
CTD |
PMID:12164941 |
|
NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions increases expression increases phosphorylation |
ISO |
Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ATF2 protein modified form] Bucladesine results in increased phosphorylation of ATF2 protein |
CTD |
PMID:26049102 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atp11a |
ATPase phospholipid transporting 11A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP11A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:76,657,752...76,767,640
Ensembl chr16:76,657,752...76,767,640
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ATP2B1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295
|
|
G |
Atp6v0c |
ATPase H+ transporting V0 subunit C |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP6V0C mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] |
CTD |
PMID:16822680 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BCAT1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCKDK mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] Bucladesine results in decreased expression of BCL2 protein |
CTD |
PMID:10697531 PMID:16822680 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l13 |
Bcl2-like 13 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCL2L13 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:154,056,116...154,112,890
Ensembl chr 4:154,056,127...154,108,985
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
ISO |
1-bromopropane inhibits the reaction [Bucladesine results in increased expression of BDNF mRNA]; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:19189864 PMID:29698629 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein-like |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BET1L mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:195,931,407...195,935,072
Ensembl chr 1:195,931,411...195,935,040
|
|
G |
Bicd1 |
BICD cargo adaptor 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BICD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:182,479,071...182,631,504
Ensembl chr 4:182,479,071...182,627,434
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA] |
CTD |
PMID:20522807 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bsnd |
barttin CLCNK type accessory subunit beta |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BSND mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:121,251,774...121,260,571
Ensembl chr 5:121,251,774...121,260,571
|
|
G |
C1r |
complement C1r |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of C1R mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CALM1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Calr |
calreticulin |
increases stability |
ISO |
Bucladesine results in increased stability of CALR protein |
CTD |
PMID:9473613 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Capn2 |
calpain 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAPN2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein]; Bucladesine promotes the reaction [Hydroxyurea results in increased activity of CASP3 protein] |
CTD |
PMID:10697531 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cast |
calpastatin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CAST mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659
|
|
G |
Cav2 |
caveolin 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAV2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein] |
CTD |
PMID:12538206 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CCN2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CCNB1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CCNB1 protein |
CTD |
PMID:22534328 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
EXP ISO |
Bucladesine results in increased expression of CCND1 protein [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] affects the expression of CCND1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 protein |
CTD |
PMID:16718685 PMID:21693435 PMID:22534328 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
EXP |
Bucladesine results in increased expression of CCND3 protein |
CTD |
PMID:16718685 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Cd69 |
Cd69 molecule |
decreases expression |
ISO |
Bucladesine results in decreased expression of CD69 protein |
CTD |
PMID:25433234 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein] |
CTD |
PMID:12538815 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cdc42bpa |
CDC42 binding protein kinase alpha |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CDC42BPA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:91,683,775...91,903,732
Ensembl chr13:91,684,007...91,903,732
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
EXP ISO |
Bucladesine results in increased expression of CDKN1A protein GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein] [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CDKN1A protein |
CTD |
PMID:16718685 PMID:20823114 PMID:22534328 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP |
Bucladesine results in increased expression of CDKN1B protein |
CTD |
PMID:16718685 PMID:21693435 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of CEBPB protein Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of CEBPB protein] |
CTD |
PMID:19282384 PMID:19698295 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CEBPZ mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions increases expression |
ISO EXP |
[Bucladesine co-treated with Tretinoin] results in increased activity of CHAT protein; [Tretinoin co-treated with Bucladesine] results in increased activity of CHAT protein Nicotine promotes the reaction [Bucladesine results in increased expression of CHAT protein] |
CTD |
PMID:16724269 PMID:20361958 PMID:29665406 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Cldn5 |
claudin 5 |
increases expression |
ISO |
Bucladesine results in increased expression of CLDN5 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Cngb1 |
cyclic nucleotide gated channel subunit beta 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CNGB1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:9,726,595...9,791,111
Ensembl chr19:9,726,595...9,791,173
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:11576339 PMID:16430859 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] |
CTD |
PMID:11576339 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of COX6A2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274
|
|
G |
Cplx1 |
complexin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CPLX1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:1,184,677...1,216,392
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation multiple interactions |
ISO |
Bucladesine results in increased phosphorylation of CREB1 protein [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of CREB1 protein] [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]] |
CTD |
PMID:12164941 PMID:18787026 PMID:19282384 PMID:36565944 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]] [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]] |
CTD |
PMID:19282384 PMID:20685861 PMID:36565944 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CREM mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
EXP |
Bucladesine inhibits the reaction [arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:8769853 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
Bucladesine promotes the reaction [Tretinoin results in increased expression of CSF1R mRNA] |
CTD |
PMID:8445950 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
multiple interactions affects localization |
ISO |
Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein]; Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein] Bucladesine affects the localization of CTBP1 protein |
CTD |
PMID:18184656 |
|
NCBI chr14:77,455,580...77,482,821
Ensembl chr14:77,455,696...77,482,821
|
|
G |
Ctbp2 |
C-terminal binding protein 2 |
affects localization multiple interactions |
ISO |
Bucladesine affects the localization of CTBP2 protein Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein] |
CTD |
PMID:18184656 |
|
NCBI chr 1:187,782,064...187,918,115
Ensembl chr 1:187,782,682...187,920,222
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases phosphorylation |
EXP |
Bucladesine results in increased phosphorylation of CTNNB1 protein |
CTD |
PMID:26964897 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctps2 |
CTP synthase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CTPS2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:31,645,873...31,786,733
Ensembl chr X:31,645,873...31,786,733
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Bucladesine results in decreased expression of CXCL12 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cyb5d1 |
cytochrome b5 domain containing 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CYB5D1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:54,113,428...54,117,744
Ensembl chr10:54,113,438...54,117,911
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression multiple interactions |
EXP ISO |
Bucladesine results in increased expression of CYP11A1 mRNA [Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA] fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA] |
CTD |
PMID:21693180 PMID:21979172 PMID:23200735 PMID:35987080 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of CYP11B1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP11B1 mRNA] |
CTD |
PMID:35987080 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
fluorene-9-bisphenol affects the reaction [Bucladesine results in increased expression of CYP11B2 mRNA] |
CTD |
PMID:35987080 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions increases expression |
EXP ISO |
Bucladesine results in decreased expression of CYP17A1 mRNA [Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA] Bucladesine results in increased expression of CYP17A1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:21458522 PMID:21693180 PMID:23200735 PMID:35987080 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of CYP19A1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:35987080 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP ISO |
Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:1849469 PMID:16901605 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:1849469 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
Bucladesine results in increased expression of CYP1B1 mRNA |
CTD |
PMID:11559018 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Bucladesine promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol] |
CTD |
PMID:8531136 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein] |
CTD |
PMID:20823114 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddx27 |
DEAD-box helicase 27 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DDX27 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:155,744,182...155,763,380
Ensembl chr 3:155,744,150...155,763,372
|
|
G |
Des |
desmin |
multiple interactions |
EXP ISO |
[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of DES mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA |
CTD |
PMID:19089455 PMID:20823114 |
|
NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
|
|
G |
Dhx9 |
DExH-box helicase 9 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DHX9 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DIO2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dtymk |
deoxythymidylate kinase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DTYMK mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:94,315,552...94,324,386
Ensembl chr 9:94,315,552...94,324,870
|
|
G |
Eda |
ectodysplasin-A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EDA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:65,078,454...65,480,172
Ensembl chr X:65,078,673...65,480,172
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EEF1A1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EFEMP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EGR2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Epb41l4a |
erythrocyte membrane protein band 4.1 like 4A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPB41L4A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:25,405,461...25,615,392
Ensembl chr18:25,406,057...25,615,149
|
|
G |
Epha3 |
Eph receptor A3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPHA3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression multiple interactions |
EXP |
Bucladesine results in increased expression of ESR1 mRNA [Quercetin co-treated with Bucladesine] results in increased expression of ESR1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of ESR1 mRNA] |
CTD |
PMID:21693180 PMID:23200735 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EYA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
multiple interactions |
ISO |
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]] |
CTD |
PMID:36565944 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FADS2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression multiple interactions |
EXP |
Bucladesine results in increased expression of FAS mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of FAS mRNA] |
CTD |
PMID:12414803 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fbxo11 |
F-box protein 11 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXO11 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:6,486,761...6,562,664
Ensembl chr 6:6,486,015...6,562,662
|
|
G |
Fbxw5 |
F-box and WD repeat domain containing 5 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXW5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:8,322,543...8,327,092
Ensembl chr 3:8,322,543...8,327,092
|
|
G |
Fcer2 |
Fc epsilon receptor II |
decreases expression |
ISO |
Bucladesine results in decreased expression of FCER2 protein |
CTD |
PMID:1328389 |
|
NCBI chr12:1,742,809...1,754,476
Ensembl chr12:1,742,815...1,754,476
|
|
G |
Fgd1 |
FYVE, RhoGEF and PH domain containing 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FGD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:20,023,746...20,066,734
Ensembl chr X:20,023,746...20,066,566
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions |
ISO |
FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; FGF9 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone] |
CTD |
PMID:22798350 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Filip1l |
filamin A interacting protein 1-like |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FILIP1L mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:42,937,353...43,177,085
Ensembl chr11:42,940,467...43,177,415
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
[bisphenol A co-treated with Bucladesine] results in increased methylation of FKBP5 intron; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 protein; [Bucladesine co-treated with Dexamethasone] results in increased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 protein; [fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron; bisphenol A promotes the reaction [[fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron]; Dexamethasone inhibits the reaction [[Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA]; Estradiol inhibits the reaction [[Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA] |
CTD |
PMID:26427651 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
affects expression increases expression multiple interactions |
ISO |
Bucladesine affects the expression of FOS protein Bucladesine results in increased expression of FOS mRNA; Bucladesine results in increased expression of FOS protein Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein] |
CTD |
PMID:7798212 PMID:9187264 PMID:19282384 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein] |
CTD |
PMID:20823114 PMID:36682589 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fscn2 |
fascin actin-bundling protein 2, retinal |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FSCN2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:105,634,783...105,641,322
Ensembl chr10:105,634,783...105,641,322
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions increases expression |
ISO |
IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC1 mRNA]; STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]] Bucladesine results in increased expression of G6PC1 mRNA; Bucladesine results in increased expression of G6PC1 protein |
CTD |
PMID:22859313 PMID:26064446 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gars1 |
glycyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GARS1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609
|
|
G |
Gbe1 |
1,4-alpha-glucan branching enzyme 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GBE1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:8,734,806...9,000,226
Ensembl chr11:8,734,820...9,000,210
|
|
G |
Gbp2 |
guanylate binding protein 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GBP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GCNT2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611
|
|
G |
Gdf3 |
growth differentiation factor 3 |
affects expression multiple interactions |
ISO |
Bucladesine affects the expression of GDF3 mRNA; Bucladesine affects the expression of GDF3 protein bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 protein]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 protein] |
CTD |
PMID:31400064 |
|
NCBI chr 4:155,831,572...155,835,953
Ensembl chr 4:155,830,909...155,835,937
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
ISO |
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]] |
CTD |
PMID:36565944 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GIPC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:24,474,291...24,487,083
Ensembl chr19:24,453,123...24,486,997
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases expression |
EXP |
GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein]; Tolbutamide promotes the reaction [Bucladesine results in increased expression of GJA1 protein] |
CTD |
PMID:11741589 PMID:16718685 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gpd1 |
glycerol-3-phosphate dehydrogenase 1 |
multiple interactions |
ISO |
Bucladesine promotes the reaction [Bezafibrate results in increased expression of GPD1 mRNA] |
CTD |
PMID:1976021 |
|
NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529
|
|
G |
Gpkow |
G patch domain and KOW motifs |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GPKOW mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:14,791,601...14,806,384
Ensembl chr X:14,791,610...14,806,384
|
|
G |
Gpnmb |
glycoprotein nmb |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GPNMB mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions increases expression |
ISO |
KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA1 mRNA] |
CTD |
PMID:26049102 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of GSTA2 mRNA KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA2 mRNA] |
CTD |
PMID:26049102 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of GSTA4 mRNA KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA4 mRNA] |
CTD |
PMID:26049102 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Bucladesine results in increased expression of HIF1A mRNA |
CTD |
PMID:18591213 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions increases expression |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] inhibits the reaction [Bucladesine results in increased expression of HMGCR mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of HMGCR mRNA] |
CTD |
PMID:35987080 PMID:38603619 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hoxa1 |
homeobox A1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA] |
CTD |
PMID:20823114 |
|
NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
decreases expression multiple interactions |
ISO |
Bucladesine results in decreased expression of HSD17B1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in decreased expression of HSD17B1 mRNA] |
CTD |
PMID:35987080 |
|
NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927
|
|
G |
Hsd17b12 |
hydroxysteroid (17-beta) dehydrogenase 12 |
increases expression |
EXP |
Bucladesine results in increased expression of HSD17B12 mRNA |
CTD |
PMID:21458522 |
|
NCBI chr 3:79,990,048...80,113,556
Ensembl chr 3:79,990,056...80,113,617
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression |
EXP |
Bucladesine results in increased expression of HSD3B1 mRNA |
CTD |
PMID:21458522 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of HSD3B2 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of HSD3B2 mRNA] |
CTD |
PMID:35987080 |
|
NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression increases phosphorylation |
EXP ISO |
Bucladesine results in increased expression of HSP27 protein Bucladesine results in increased phosphorylation of HSPB1 protein |
CTD |
PMID:7541446 PMID:10559386 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of HTR1A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Iapp |
islet amyloid polypeptide |
increases expression |
EXP |
Bucladesine results in increased expression of IAPP mRNA |
CTD |
PMID:9142872 |
|
NCBI chr 4:175,237,107...175,244,373
Ensembl chr 4:175,237,115...175,242,920
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:12538815 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of ID1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ID1 mRNA] |
CTD |
PMID:20522807 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Ifrd2 |
interferon-related developmental regulator 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IFRD2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:108,260,969...108,266,191
Ensembl chr 8:108,260,969...108,266,194
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]; FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone] |
CTD |
PMID:22798350 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of IGFBP1 [Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein] |
CTD |
PMID:12093828 PMID:20823114 PMID:30328349 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Ighe |
immunoglobulin heavy constant epsilon |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]] |
CTD |
PMID:12230500 |
|
|
|
G |
Il10 |
interleukin 10 |
decreases expression multiple interactions |
ISO |
Bucladesine results in decreased expression of IL10 Bucladesine promotes the reaction [Zymosan results in increased expression of IL10 protein] |
CTD |
PMID:11301049 PMID:19273625 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IL12B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
decreases expression decreases secretion |
ISO |
Bucladesine results in decreased expression of IL13 mRNA Bucladesine results in decreased secretion of IL13 protein |
CTD |
PMID:16083514 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]; Dipyridamole promotes the reaction [Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]] |
CTD |
PMID:8904084 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of IL23A mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of IL23A mRNA |
CTD |
PMID:19273625 PMID:20823114 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression |
ISO |
Bucladesine results in decreased expression of IL2RA protein |
CTD |
PMID:1709825 PMID:25433234 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL4 protein] |
CTD |
PMID:11886533 PMID:12230500 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL5 protein] |
CTD |
PMID:11886533 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Bucladesine co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:20388727 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
decreases expression multiple interactions |
EXP |
Bucladesine results in decreased expression of INHA mRNA [Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA; Atrazine inhibits the reaction [Bucladesine results in decreased expression of INHA mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA] |
CTD |
PMID:21693180 PMID:23200735 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Insl3 |
insulin-like 3 |
multiple interactions increases expression |
EXP |
[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of INSL3 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA] |
CTD |
PMID:21458522 PMID:21693180 PMID:23200735 |
|
NCBI chr16:18,398,682...18,400,566
Ensembl chr16:18,384,829...18,400,560
|
|
G |
Ints7 |
integrator complex subunit 7 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of INTS7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:103,155,123...103,207,953
Ensembl chr13:103,155,090...103,208,592
|
|
G |
Irf9 |
interferon regulatory factor 9 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IRF9 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ISG20L2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:173,396,780...173,407,102
Ensembl chr 2:173,396,780...173,406,614
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITGB1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itih5 |
inter-alpha-trypsin inhibitor heavy chain 5 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITIH5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:68,248,115...68,352,216
Ensembl chr17:68,252,128...68,352,207
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of JUN mRNA; Bucladesine results in increased expression of JUN protein [Bucladesine co-treated with ciglitazone] results in increased expression of and results in increased phosphorylation of JUN protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of JUN mRNA]; Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein; ciglitazone promotes the reaction [Bucladesine results in increased expression of JUN mRNA]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein] Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein modified form]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein] Bucladesine results in increased expression of JUN protein; Bucladesine results in increased expression of JUN protein modified form |
CTD |
PMID:9187264 PMID:18755854 PMID:19282384 PMID:19698295 PMID:26049102 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kat2a |
lysine acetyltransferase 2A |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein] |
CTD |
PMID:18184656 |
|
NCBI chr10:85,632,216...85,640,561
Ensembl chr10:85,632,216...85,640,166
|
|
G |
Kcnc4 |
potassium voltage-gated channel subfamily C member 4 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KCNC4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:195,063,967...195,100,244
Ensembl chr 2:195,071,769...195,099,233
|
|
G |
Kng1 |
kininogen 1 |
increases activity |
EXP |
Bucladesine results in increased activity of KNG1 |
CTD |
PMID:1334751 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Krt8 |
keratin 8 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA] |
CTD |
PMID:20823114 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Lamb2 |
laminin subunit beta 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LAMB2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LDHA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
Bucladesine results in decreased expression of LEP mRNA |
CTD |
PMID:9002984 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lgals3 |
galectin 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of LGALS3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
decreases expression multiple interactions |
EXP |
Bucladesine results in decreased expression of LHCGR mRNA [Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA] |
CTD |
PMID:21693180 PMID:23200735 |
|
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Lipe |
lipase E, hormone sensitive type |
affects localization multiple interactions increases expression increases activity |
EXP ISO |
Bucladesine affects the localization of LIPE protein [Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein; CAY 10499 inhibits the reaction [Bucladesine results in increased activity of and results in increased phosphorylation of LIPE protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of LIPE mRNA]; NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]; NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] Bucladesine results in increased activity of LIPE protein |
CTD |
PMID:11160373 PMID:23362264 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
LOC120095955 |
mucin-12-like |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MUC12 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:19,486,041...19,493,995
|
|
G |
Lpar3 |
lysophosphatidic acid receptor 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LPAR3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:235,149,065...235,193,357
|
|
G |
Ltbp1 |
latent transforming growth factor beta binding protein 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LTBP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:20,029,629...20,425,339
Ensembl chr 6:20,029,629...20,425,349
|
|
G |
Ltc4s |
leukotriene C4 synthase |
decreases secretion |
ISO |
Bucladesine results in decreased secretion of LTC4S protein |
CTD |
PMID:16083514 |
|
NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651
|
|
G |
Map1a |
microtubule-associated protein 1A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MAP1A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Map4k4 |
mitogen-activated protein kinase kinase kinase kinase 4 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MAP4K4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK1 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein]] |
CTD |
PMID:8526880 PMID:19282384 PMID:22875961 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK3 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein]] |
CTD |
PMID:8526880 PMID:19282384 PMID:22875961 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgat4b |
alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MGAT4B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:34,548,918...34,559,229
Ensembl chr10:34,549,433...34,559,229
|
|
G |
Mir125a |
microRNA 125a |
decreases expression |
EXP ISO |
Bucladesine results in decreased expression of MIR125A mRNA |
CTD |
PMID:23045399 |
|
NCBI chr 1:58,677,626...58,677,710
Ensembl chr 1:58,677,626...58,677,710
|
|
G |
Mir145 |
microRNA 145 |
decreases expression |
EXP ISO |
Bucladesine results in decreased expression of MIR145 mRNA |
CTD |
PMID:23045399 |
|
NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727
|
|
G |
Mir27b |
microRNA 27b |
multiple interactions |
ISO |
[Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MIR27B mRNA |
CTD |
PMID:30328349 |
|
NCBI chr17:1,813,427...1,813,523
Ensembl chr17:1,813,426...1,813,529
|
|
G |
Mir455 |
microRNA 455 |
decreases expression |
EXP ISO |
Bucladesine results in decreased expression of MIR455 mRNA |
CTD |
PMID:23045399 |
|
NCBI chr 5:76,689,313...76,689,390
Ensembl chr 5:76,689,313...76,689,390
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
Bucladesine results in decreased expression of MKI67 protein |
CTD |
PMID:16718685 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MMP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTR mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Bucladesine results in decreased expression of MYC mRNA; Bucladesine results in decreased expression of MYC protein |
CTD |
PMID:7798212 PMID:9187264 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh9 |
myosin, heavy chain 9 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYH9 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:109,343,718...109,424,457
Ensembl chr 7:109,343,706...109,424,457
|
|
G |
Myl12a |
myosin light chain 12A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580
|
|
G |
Myl12b |
myosin light chain 12B |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:110,873,855...110,888,187
|
|
G |
Mylk |
myosin light chain kinase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Myof |
myoferlin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYOF mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NCF1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ndst1 |
N-deacetylase and N-sulfotransferase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NDST1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:54,136,887...54,199,545
Ensembl chr18:54,140,779...54,178,191
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA |
CTD |
PMID:29698629 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nefm |
neurofilament medium chain |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:29698629 |
|
NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Neurog1 |
neurogenin 1 |
multiple interactions affects expression |
ISO |
bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 protein] Bucladesine affects the expression of NEUROG1 mRNA; Bucladesine affects the expression of NEUROG1 protein |
CTD |
PMID:31400064 |
|
NCBI chr17:8,362,878...8,364,397
Ensembl chr17:8,362,821...8,364,571
|
|
G |
Nexn |
nexilin (F actin binding protein) |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NEXN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:241,186,783...241,218,315
Ensembl chr 2:241,186,790...241,218,342
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases response to substance |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of CYP2A5 mRNA]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC1 mRNA] |
CTD |
PMID:22859313 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nom1 |
nucleolar protein with MIF4G domain 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NOM1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:5,891,220...5,910,741
Ensembl chr 4:5,892,909...5,909,709
|
|
G |
Nphp1 |
nephrocystin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NPHP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:114,960,650...115,016,234
Ensembl chr 3:114,960,650...115,016,234
|
|
G |
Nptxr |
neuronal pentraxin receptor |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NPTXR mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:111,336,660...111,354,737
Ensembl chr 7:111,336,664...111,354,802
|
|
G |
Npy |
neuropeptide Y |
increases expression |
EXP |
Bucladesine results in increased expression of NPY mRNA |
CTD |
PMID:19912776 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression multiple interactions |
ISO |
Bucladesine results in decreased expression of NR0B1 mRNA; Bucladesine results in decreased expression of NR0B1 protein Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 protein]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]] |
CTD |
PMID:18787026 PMID:19282384 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] |
CTD |
PMID:23362264 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] |
CTD |
PMID:23362264 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NR2F1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions increases expression |
ISO |
NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of NR4A1 protein] [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]] |
CTD |
PMID:18787026 PMID:19282384 PMID:36565944 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions increases expression |
ISO |
Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of NR5A1 mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of NR5A1 protein] NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA] Bucladesine results in increased expression of NR5A1 mRNA; Bucladesine results in increased expression of NR5A1 protein |
CTD |
PMID:18184656 PMID:18787026 PMID:35987080 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NRIP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761
|
|
G |
Nt5e |
5' nucleotidase, ecto |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NT5E mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Ntf3 |
neurotrophin 3 |
increases expression |
EXP |
Bucladesine results in increased expression of NTF3 protein |
CTD |
PMID:19854260 |
|
NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596
|
|
G |
Nts |
neurotensin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NTS mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Nup155 |
nucleoporin 155 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NUP155 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:57,201,310...57,252,918
Ensembl chr 2:57,201,272...57,254,148
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions decreases activity |
ISO |
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [Bucladesine results in decreased activity of ODC1 protein] |
CTD |
PMID:6284819 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Ogfrl1 |
opioid growth factor receptor-like 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OGFRL1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:25,828,865...25,842,424
Ensembl chr 9:25,828,869...25,842,352
|
|
G |
Or8b8 |
olfactory receptor family 8 subfamily B member 8 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OR8B8 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:37,693,578...37,694,510
Ensembl chr 8:37,693,499...37,694,547
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of P4HB mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Paep |
progestagen associated endometrial protein |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PAEP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:8,531,136...8,534,430
Ensembl chr 3:8,531,138...8,534,430
|
|
G |
Pakap |
paralemmin A kinase anchor protein |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PALM2AKAP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:72,536,986...72,648,524 NCBI chr 5:72,313,646...72,450,645
Ensembl chr 5:72,181,718...72,648,524
|
|
G |
Pax6 |
paired box 6 |
multiple interactions affects expression |
ISO |
bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 protein]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 protein] Bucladesine affects the expression of PAX6 mRNA; Bucladesine affects the expression of PAX6 protein |
CTD |
PMID:31400064 |
|
NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
|
|
G |
Pcdh18 |
protocadherin 18 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDH18 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:133,831,996...133,845,992
Ensembl chr 2:133,832,001...133,845,883
|
|
G |
Pcdhb5 |
protocadherin beta 5 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDHB4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:29,024,315...29,032,183
Ensembl chr18:29,028,382...29,053,259
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions increases expression |
ISO EXP |
Metformin inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA] Lithium Chloride inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA] |
CTD |
PMID:1371108 PMID:24428821 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
decreases expression |
ISO |
Bucladesine results in decreased expression of PDGFA mRNA |
CTD |
PMID:1650039 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PDK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pf4 |
platelet factor 4 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PF4 mRNA [Bucladesine co-treated with Tetrachlorodibenzodioxin] results in increased expression of PF4 mRNA |
CTD |
PMID:21979172 |
|
NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Pgrmc2 |
progesterone receptor membrane component 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PGRMC2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:124,068,257...124,084,155
Ensembl chr 2:124,068,260...124,084,155
|
|
G |
Pitpnc1 |
phosphatidylinositol transfer protein, cytoplasmic 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PITPNC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:92,163,558...92,428,971
Ensembl chr10:92,167,196...92,429,297
|
|
G |
Pkd2l1 |
polycystin 2 like 1, transient receptor potential cation channel |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PKD2L1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:243,032,891...243,070,031
Ensembl chr 1:243,032,913...243,070,031
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLAT mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plekhg3 |
pleckstrin homology and RhoGEF domain containing G3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLEKHG3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:95,265,756...95,308,952
Ensembl chr 6:95,266,058...95,310,359
|
|
G |
Plin1 |
perilipin 1 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PLIN1 mRNA LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA] |
CTD |
PMID:23362264 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Pls3 |
plastin 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PLS3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:111,589,193...111,683,908
Ensembl chr X:111,589,254...111,683,891
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
multiple interactions increases activity |
ISO |
Ascorbic Acid inhibits the reaction [Bucladesine results in increased activity of PMP22 promoter] |
CTD |
PMID:15034573 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PNPLA6 mRNA Bucladesine results in increased expression of and results in increased activity of PNPLA6 protein; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein] |
CTD |
PMID:20380879 |
|
NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734
|
|
G |
Pomc |
proopiomelanocortin |
increases expression |
ISO |
Bucladesine results in increased expression of POMC mRNA; Bucladesine results in increased expression of POMC protein modified form |
CTD |
PMID:1325994 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
affects expression multiple interactions |
ISO |
Bucladesine affects the expression of POU5F1 mRNA; Bucladesine affects the expression of POU5F1 protein bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 protein] |
CTD |
PMID:31400064 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PPARG protein [ciglitazone co-treated with Bucladesine] affects the expression of PPARG mRNA; [ciglitazone co-treated with Bucladesine] results in increased expression of PPARG protein |
CTD |
PMID:19698295 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PPARGC1A mRNA; Bucladesine results in increased expression of PPARGC1A protein IL22 protein inhibits the reaction [Bucladesine results in increased expression of PPARGC1A protein]; Metformin inhibits the reaction [Bucladesine results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:24428821 PMID:26064446 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppia |
peptidylprolyl isomerase A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PPIA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
increases expression |
EXP |
Bucladesine results in increased expression of PRIMA1 mRNA |
CTD |
PMID:18514641 |
|
NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions increases activity |
EXP |
KT 5720 inhibits the reaction [Bucladesine results in increased activity of PRKACA protein] |
CTD |
PMID:31300867 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
[Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL protein; [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]; Losartan inhibits the reaction [AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]] |
CTD |
PMID:20823114 PMID:30328349 PMID:36682589 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prss12 |
serine protease 12 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PRSS12 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:211,624,134...211,684,126
Ensembl chr 2:211,624,134...211,684,126
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 protein]]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:11095985 PMID:12164941 PMID:24003391 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk7 |
protein tyrosine kinase 7 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTK7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:14,352,155...14,418,473
Ensembl chr 9:14,351,202...14,418,494
|
|
G |
Ptpa |
protein phosphatase 2 phosphatase activator |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTPA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:13,689,742...13,720,287
Ensembl chr 3:13,689,741...13,722,549
|
|
G |
Rab1b |
RAB1B, member RAS oncogene family |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB1B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:202,405,759...202,413,850
Ensembl chr 1:202,405,759...202,413,868 Ensembl chr X:202,405,759...202,413,868
|
|
G |
Rab31 |
RAB31, member RAS oncogene family |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB31 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:105,246,712...105,382,973
Ensembl chr 9:105,246,709...105,381,253
|
|
G |
Ran |
RAN, member RAS oncogene family |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RAN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases activity multiple interactions decreases phosphorylation |
ISO EXP |
Bucladesine results in decreased activity of RB1 protein Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein] Bucladesine results in decreased phosphorylation of RB1 protein |
CTD |
PMID:10697531 PMID:16718685 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Ren |
renin |
increases secretion increases expression |
ISO |
Bucladesine results in increased secretion of REN protein Bucladesine results in increased expression of REN mRNA |
CTD |
PMID:9256163 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Ret |
ret proto-oncogene |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RET mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
|
|
G |
Rgs10 |
regulator of G-protein signaling 10 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RGS10 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:182,946,334...182,987,729
Ensembl chr 1:182,946,336...182,987,697
|
|
G |
Rhobtb3 |
Rho-related BTB domain containing 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RHOBTB3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:5,363,388...5,419,164
Ensembl chr 2:5,363,388...5,419,041
|
|
G |
Rin1 |
Ras and Rab interactor 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RIN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:202,355,729...202,362,731
Ensembl chr 1:202,355,890...202,362,729
|
|
G |
Rpn1 |
ribophorin I |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:120,543,667...120,565,069
Ensembl chr 4:120,543,667...120,565,069
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPS6KB1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rpsa |
ribosomal protein SA |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RPSA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
|
|
G |
S100a14 |
S100 calcium binding protein A14 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of S100A14 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:176,008,395...176,010,423
Ensembl chr 2:176,008,395...176,010,423
|
|
G |
Saraf |
store-operated calcium entry-associated regulatory factor |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SARAF mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:58,017,231...58,035,481
Ensembl chr16:58,017,231...58,035,545
|
|
G |
Scamp4 |
secretory carrier membrane protein 4 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SCAMP4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:9,101,504...9,113,929
Ensembl chr 7:9,101,489...9,113,967
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions increases expression |
ISO EXP |
LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA] |
CTD |
PMID:23045399 PMID:23362264 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Sdcbp |
syndecan binding protein |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SDCBP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:19,473,499...19,517,188
Ensembl chr 5:19,489,961...19,527,572
|
|
G |
Selenot |
selenoprotein T |
multiple interactions increases expression |
EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA]; nickel chloride inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA] |
CTD |
PMID:18198219 |
|
NCBI chr 2:142,804,387...142,821,438
Ensembl chr 2:142,804,405...142,821,427
|
|
G |
Sema3a |
semaphorin 3A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SEMA3A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:21,282,398...21,754,834
Ensembl chr 4:21,287,982...21,494,432
|
|
G |
Septin11 |
septin 11 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SEPTIN11 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:14,844,759...14,990,856
Ensembl chr14:14,844,580...14,990,853
|
|
G |
Sfn |
stratifin |
multiple interactions |
ISO |
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of SFN mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein |
CTD |
PMID:22534328 |
|
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Slc18a3 |
solute carrier family 18 member A3 |
increases expression multiple interactions |
EXP |
Bucladesine results in increased expression of SLC18A3 protein Nicotine promotes the reaction [Bucladesine results in increased expression of SLC18A3 protein] |
CTD |
PMID:20361958 |
|
NCBI chr16:7,713,630...7,716,491
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
[Progesterone co-treated with Bucladesine] results in increased expression of SLC2A1 protein |
CTD |
PMID:18948400 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions |
ISO |
Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA] |
CTD |
PMID:12820898 |
|
NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Smad6 |
SMAD family member 6 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA] |
CTD |
PMID:20522807 |
|
NCBI chr 8:64,450,114...64,519,673
Ensembl chr 8:64,450,114...64,519,763
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases activity increases expression |
ISO |
Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of SOD2 mRNA]; protein kinase inhibitor peptide inhibits the reaction [Bucladesine results in increased activity of SOD2 protein] |
CTD |
PMID:12093828 PMID:20685861 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox1 |
SRY-box transcription factor 1 |
multiple interactions affects expression |
ISO |
bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 protein] Bucladesine affects the expression of SOX1 mRNA; Bucladesine affects the expression of SOX1 protein |
CTD |
PMID:31400064 |
|
NCBI chr16:77,135,577...77,139,592
Ensembl chr16:77,137,584...77,138,762
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions increases expression |
ISO |
Organophosphates inhibits the reaction [Bucladesine results in increased expression of SREBF2 mRNA] |
CTD |
PMID:38603619 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Srsf7 |
serine and arginine rich splicing factor 7 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SRSF7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:14,811,775...14,818,968
Ensembl chr 6:14,811,808...14,818,965
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression decreases expression |
ISO EXP |
27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [[T0901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] which results in increased abundance of Progesterone; [Bucladesine co-treated with ciglitazone] results in increased expression of STAR mRNA; [Bucladesine co-treated with ciglitazone] results in increased phosphorylation of STAR protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone; [Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; [T0901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR protein]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [T0901317 results in increased expression of STAR mRNA]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [LG 100268 results in increased expression of STAR mRNA]]; Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA; Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein; CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR protein]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; lead acetate inhibits the reaction [Bucladesine results in increased expression of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Tetradecanoylphorbol Acetate promotes the reaction [[Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] [Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA] Bucladesine results in decreased expression of STAR mRNA Bucladesine results in increased expression of STAR mRNA; Bucladesine results in increased expression of STAR protein [IMOL S-140 co-treated with triphenyl phosphate co-treated with tris(chloroethyl)phosphate co-treated with diphenylcresyl phosphate co-treated with tert-butylphenyl diphenyl phosphate co-treated with tri-xylenyl phosphate] inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; [tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Organophosphates inhibits the reaction [Bucladesine results in increased expression of STAR mRNA] |
CTD |
PMID:10964798 PMID:10993823 PMID:11213355 PMID:18755854 PMID:18787026 PMID:19253104 PMID:19282384 PMID:19698295 PMID:20083572 PMID:21047949 PMID:21693180 PMID:21979172 PMID:23200735 PMID:23362264 PMID:35987080 PMID:38603619 More...
|
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]] |
CTD |
PMID:26064446 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stk38 |
serine/threonine kinase 38 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of STK38 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:7,034,245...7,067,803
Ensembl chr20:7,034,242...7,068,198
|
|
G |
Sulf1 |
sulfatase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SULF1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:6,362,894...6,526,174
Ensembl chr 5:6,362,911...6,525,584
|
|
G |
Tagln |
transgelin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TAGLN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tcea1 |
transcription elongation factor A1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TCEA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:14,631,454...14,668,769
Ensembl chr 5:14,631,454...14,668,745 Ensembl chr15:14,631,454...14,668,745
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TERT mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Testin |
testin gene |
decreases expression multiple interactions |
EXP |
Bucladesine results in decreased expression of TESTIN mRNA Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA]; lonidamine inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA] |
CTD |
PMID:11090432 |
|
NCBI chr17:3,824,222...3,859,385
Ensembl chr17:3,846,899...3,859,385
|
|
G |
Tfrc |
transferrin receptor |
decreases expression |
ISO |
Bucladesine results in decreased expression of TFRC protein |
CTD |
PMID:2989362 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] |
CTD |
PMID:11576339 PMID:16430859 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
[O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein; [phenylsaligenin cyclic phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein |
CTD |
PMID:32749514 |
|
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
EXP |
Bucladesine results in increased expression of TH mRNA |
CTD |
PMID:19912776 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
EXP |
Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of TJP1 protein] |
CTD |
PMID:16716901 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnc |
tenascin C |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TNC mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Bucladesine inhibits the reaction [Zymosan results in increased expression of TNF protein] Bucladesine inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Bucladesine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:11301049 PMID:12509806 PMID:12538815 PMID:15081246 PMID:20388727 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of TP53 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of TP53 protein |
CTD |
PMID:22534328 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TPI1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Tpsg1 |
tryptase gamma 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TPSG1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:14,386,352...14,390,258
Ensembl chr10:14,386,352...14,390,258
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TXN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Ube2d2b |
ubiquitin-conjugating enzyme E2D 2B |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of UBE2D4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:1,915,999...1,917,473
Ensembl chr14:1,916,845...1,917,416
|
|
G |
Ucp1 |
uncoupling protein 1 |
increases expression multiple interactions |
EXP |
Bucladesine results in increased expression of UCP1 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of UCP1 mRNA] |
CTD |
PMID:12414803 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ugcg |
UDP-glucose ceramide glucosyltransferase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of UGCG mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393
|
|
G |
Usp12 |
ubiquitin specific peptidase 12 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of USP12 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:8,309,845...8,363,686
Ensembl chr12:8,309,750...8,363,656
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
Bucladesine results in increased expression of VEGFA mRNA |
CTD |
PMID:18591213 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
[Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein |
CTD |
PMID:20823114 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vps39 |
VPS39 subunit of HOPS complex |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VPS39 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:107,266,846...107,304,884
Ensembl chr 3:107,267,310...107,304,975
|
|
G |
Wnt5a |
Wnt family member 5A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WNT5A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234
|
|
G |
Wwtr1 |
WW domain containing transcription regulator 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WWTR1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968
|
|
G |
Zbtb45 |
zinc finger and BTB domain containing 45 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZBTB45 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:73,634,895...73,639,802
Ensembl chr 1:73,635,448...73,639,556
|
|
G |
Zscan10 |
zinc finger and SCAN domain containing 10 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN10 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:12,636,302...12,646,275
Ensembl chr10:12,636,302...12,646,275
|
|
G |
Zscan20 |
zinc finger and SCAN domain containing 20 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN20 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:140,926,596...140,956,285
Ensembl chr 5:140,930,689...140,956,336
|
|